EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index

Maria J Vargas-Brochero, Ilario Russo, Tommaso Mazzierli, Anila Cara, Gian Marco Berti, Joaquim Milheiro, Charat Thongprayoon, Marco Allinovi iD, Chiara Somma, Valentina Raglianti iD, Emanuele D'Arpino, Ladan Zand und 8 weitere

Nephrology Dialysis Transplantation · 31.03.2026 · 41 (4) · 703-714

DOI: 10.1093/ndt/gfaf197 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 25.09.2025. Verfasst von Maria J Vargas-Brochero und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Proteinuria, Body Mass Index, Glomerulonephritis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium–glucose co-transporter 2 inhibitors (SGLT2is) are emerging as an essential part of the standard of care for proteinuria in patients with chronic kidney disease. To date, no study has specifically evaluated the effects of body mass index (BMI) on the antiproteinuric efficacy of SGLT2is. Here we report the impact of BMI on the antiproteinuric efficacy of SGLT2is in non-diabetic patients with glomerular diseases.

Methods

This is a retrospective, multicentre, international observational cohort study that included non-diabetic patients with biopsy-proven glomerular disease and proteinuria >0.5 g/24 h who received SGLT2is between 2016 and 2023. Laboratory values, including proteinuria and estimated glomerular filtration rate (eGFR), were obtained at baseline and after 3–6 months. Changes in laboratory values over time were analysed using the paired signed-rank test.

Results

A total of 300 patients met the inclusion criteria. The median age was 51.82 years [interquartile range (IQR) 41–62.65], 64.7% were male and 92.7% were white. The most common glomerular disease was immunoglobulin A nephropathy (40.3%). The median eGFR was 52.26 ml/min/1.73 m2 (IQR 36.41–74.01), the median proteinuria was 1.60 g/24 h (IQR 1.15–2.91) and the median serum albumin was 4.08 g/dl (IQR 3.80–4.30). Proteinuria reduction after SGLT2i initiation was significant only in overweight and obese patients (P < .001 versus 0.18). Patients with normal BMI did not experience the expected early decrease in eGFR (P = .16).

Conclusions

SGLT2is are ineffective in proteinuria reduction in patients with a BMI <25 kg/m2, which contrasts with the significant proteinuria reduction in overweight and obese patients with glomerulopathies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsProteinuriaBody Mass IndexGlomerulonephritisHumansMaleFemaleMiddle AgedRetrospective StudiesGlomerular Filtration RateAdultPrognosisFollow-Up Studies

Stichwörter der Autor:innen

body mass indexglomerular diseaseproteinuriasodium–glucose co-transporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
  • Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy.
  • Nephrology and Dialysis Firenze 2, Azienda USL Toscana Centro, Florence, Italy.
  • Renal Division, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - University of Bologna, Bologna, Italy.
  • Nephrology Department, Local Health Unit Viseu Dão-Lafões, Viseu, Portugal.

ORCID-Profile: Marco Allinovi, Valentina Raglianti, Maria Jose Soler, Sanjeev Sethi, Manuel Praga, Fernando Caravaca-Fontan, Paola Romagnani, Fernando C Fervenza

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Vargas-Brochero, M. J., Russo, I., Mazzierli, T., Cara, A., Berti, G. M., Milheiro, J., Thongprayoon, C., Allinovi, M., Somma, C., Raglianti, V., D'Arpino, E., Zand, L., Nuñez-Delgado, S., Soler, M. J., Sethi, S., Gutiérrez, E., Praga, M., Caravaca-Fontan, F., Romagnani, P., & Fervenza, F. C. (2026). Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index. Nephrology Dialysis Transplantation, 41(4), 703-714. https://doi.org/10.1093/ndt/gfaf197

Vancouver

Vargas-Brochero MJ, Russo I, Mazzierli T, Cara A, Berti GM, Milheiro J, et al. Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index. Nephrology Dialysis Transplantation. 2026;41(4):703-714. doi:10.1093/ndt/gfaf197

BibTeX
@article{VargasBrochero2026,
  author = {Vargas-Brochero, Maria J and Russo, Ilario and Mazzierli, Tommaso and Cara, Anila and Berti, Gian Marco and Milheiro, Joaquim and Thongprayoon, Charat and Allinovi, Marco and Somma, Chiara and Raglianti, Valentina and D'Arpino, Emanuele and Zand, Ladan and Nuñez-Delgado, Sara and Soler, Maria Jose and Sethi, Sanjeev and Gutiérrez, Eduardo and Praga, Manuel and Caravaca-Fontan, Fernando and Romagnani, Paola and Fervenza, Fernando C},
  title = {Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  volume = {41},
  number = {4},
  pages = {703--714},
  doi = {10.1093/ndt/gfaf197}
}
Kostenlos starten →